OncoMatch/Clinical Trials/NCT07093814
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Is NCT07093814 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies VRT106 for glioblastoma.
Treatment: VRT106 — This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: oncolytic virus
Previously received treatment with oncolytic viruses
Cannot have received: gene therapy
Previously received treatment with...gene therapy
Cannot have received: clinical investigational drug/device
Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify